Literature DB >> 35855199

Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas.

Priscila de Medeiros Souza1, Filomena Marino Carvalho2, Fernando N Aguiar3, Débora Gagliato4, Alfredo Carlos Simões Dornellas de Barros1,5.   

Abstract

Objective: This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. Materials and
Methods: GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression.
Results: GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity.
Conclusion: High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors. ©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.

Entities:  

Keywords:  Breast cancer; GATA3 expression; histopathology; immunohistochemistry

Year:  2022        PMID: 35855199      PMCID: PMC9255655          DOI: 10.4274/ejbh.galenos.2022.2022-3-9

Source DB:  PubMed          Journal:  Eur J Breast Health


  24 in total

1.  Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer.

Authors:  Kyueng-Whan Min; Dong-Hoon Kim; Sung-Im Do; Seoung Wan Chae; Kyungeun Kim; Jin Hee Sohn; Jung-Soo Pyo; Hyun Joo Lee; Dong Hyun Kim; Sukjoong Oh; Seon Hyeong Choi; Yong Lai Park; Chan Heun Park; Eun-Kyung Kim; Mi Jung Kwon; Jinwon Seo; Kyoung Min Moon
Journal:  Virchows Arch       Date:  2015-12-30       Impact factor: 4.064

2.  Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer.

Authors:  M Husni Cangara; Upik A Miskad; Rina Masadah; Berti J Nelwan; Syarifuddin Wahid
Journal:  Breast Dis       Date:  2021-05-27

3.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.

Authors:  Rohit Mehra; Sooryanarayana Varambally; Lei Ding; Ronglai Shen; Michael S Sabel; Debashis Ghosh; Arul M Chinnaiyan; Celina G Kleer
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 4.  GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?

Authors:  Motoki Takaku; Sara A Grimm; Paul A Wade
Journal:  Gene Expr       Date:  2015

5.  Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics.

Authors:  Shan Yu; Xuepeng Jiang; Juan Li; Chao Li; Mian Guo; Fei Ye; Maomao Zhang; Yufei Jiao; Baoliang Guo
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

6.  Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.

Authors:  Gianluca Lopez; Jole Costanza; Matteo Colleoni; Laura Fontana; Stefano Ferrero; Monica Miozzo; Nicola Fusco
Journal:  Int J Mol Sci       Date:  2019-01-25       Impact factor: 5.923

7.  The significance of highlighting the oestrogen receptor low category in breast cancer.

Authors:  Ivan K Poon; Julia Y Tsang; Joshua Li; Siu-Ki Chan; Ka-Ho Shea; Gary M Tse
Journal:  Br J Cancer       Date:  2020-07-27       Impact factor: 7.640

8.  Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.

Authors:  Andliena Tahiri; Xavier Tekpli; Somisetty V Satheesh; Rik DeWijn; Torben Lüders; Ida R Bukholm; Antoni Hurtado; Jürgen Geisler; Vessela N Kristensen
Journal:  Breast Cancer Res Treat       Date:  2020-07-24       Impact factor: 4.872

9.  GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature.

Authors:  Patrizia Querzoli; Massimo Pedriali; Rosa Rinaldi; Paola Secchiero; Paolo Giorgi Rossi; Elisabetta Kuhn
Journal:  Diagnostics (Basel)       Date:  2021-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.